Erectile dysfunction is a prognostic indicator of comorbidities in men with late onset hypogonadism

Aging Male

Volumn 18, Issue 3, 2015, Pages 186-194

  Almehmadi, Yousef ^a   Yassin, Dany Jan ^b   Yassin, Aksam A ^a,c  

^a Institute of Urology Andrology   (Germany)

^b KLINIKUM BRAUNSCHWEIG   (Germany)

^c DRESDEN INTERNATIONAL UNIVERSITY   (Germany)

Author keywords

Erectile dysfunction; hypogonadism; metabolic syndrome; testosterone

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; AGED; AGING MALES SYMPTOM; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMORBIDITY; DISEASE SEVERITY ASSESSMENT; ERECTILE DYSFUNCTION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGONADISM; INSULIN DEPENDENT DIABETES MELLITUS; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; LATE ONSET DISORDER; MIDDLE AGED; PROGNOSIS; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COMORBIDITY; ERECTILE DYSFUNCTION; HUMANS; HYPOGONADISM; LATE ONSET DISORDERS; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES;

EID: 84942508471     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.3109/13685538.2015.1046044     Document Type: Article

References (75)

1. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991; 73: 1016-25.
2. Camacho EM, Huhtaniemi IT, O'Neill TW, et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol 2013; 168: 445-55.
3. Gates MA, Mekary RA, Chiu GR, et al. Sex steroid hormone levels and body composition in men. J Clin Endocrinol Metab 2013; 98: 2442-50.
4. Saboor Aftab SA, Kumar S, Barber TM. The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism. Clin Endocrinol (Oxf) 2013; 78: 330-7.
5. Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 2015; 18: 5-15.
6. Malkin CJ, Pugh PJ, Morris PD, et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010; 96: 1821-25.
7. Kapoor D, Aldred H, Clark S, et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007; 30: 911-7.
8. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011; 8: 272-83.
9. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006; 295: 1288-99.
10. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007; 116: 2694-701.
11. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93: 68-75.
12. Ponikowska B, Jankowska EA, Maj J, et al. Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease. Int J Cardiol 2010; 143: 343-8.
13. Jones TH. Cardiovascular risk during androgen deprivation therapy for prostate cancer. BMJ 2011; 24: 342:d3105.
14. Laaksonen DE, Niskanen L, Punnonen K, et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 2005; 90: 712-9.
15. Wald M, Meacham RB, Ross LS, Niederberger CS. Testosterone replacement therapy for older men. J Androl 2006; 27: 126-32.
16. Kwan M, Greenleaf WJ, Mann J, et al. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab 1983; 57: 557-62.
17. Isidori AM, Buvat J, Corona G, et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol 2014; 65: 99-112.
18. Buvat J, Bou Jaoudé G. Significance of hypogonadism in erectile dysfunction. World J Urol 2006; 24: 657-67.
19. Mikhail N. Does testosterone have a role in erectile function? Am J Med 2006; 119: 373-82.
20. Saad F, Gooren L, Haider A, Yassin A. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl 2007; 53: 353-7.
21. Kaiser FE, Viosca SP, Morley JE, et al. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc 1988; 36: 511-9.
22. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
23. Kratzik CW, Schatzl G, Lunglmayr G, et al. The impact of age, body mass index and testosterone on erectile dysfunction. J Urol 2005; 174: 240-3.
24. Cuéllar de León AJ, Ruiz García V, Campos González JC, et al. Prevalence erectile dysfunction in patients with hypertension. Med Clin (Barc) 2002; 119: 521-6.
25. Bacon CG, Mittleman MA, Kawachi I, et al. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med 2003; 139: 161-8.
26. Bortolotti A, Fedele D, Chatenoud L, et al. Cigarette smoking: a risk factor for erectile dysfunction in diabetics. Eur Urol 2001; 40: 392-6.
27. McCulloch DK, Campbell IW, Wu FC, et al. Impotence in diabetic and non-diabetic hospital outpatients. BMJ 1980; 281: 1216.
28. Romeo JH, Seftel AD, Madhun ZT, Aron DC. Sexual function in men with diabetes type 2: association with glycemic control. J Urol 2000; 163: 788-91.
29. Ponholzer A, Temml C, Mock K, et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 2005; 47: 80-5; discussion 85-6.
30. Rhoden EL, Ribeiro EP, Riedner CE, et al. Glycosylated haemoglobin levels and the severity of erectile function in diabetic men. BJU Int 2005; 95: 615-7.
31. Kapoor D, Clarke S, Channer KS, Jones TH. Erectile dysfunction is associated with low bioactive testosterone levels and visceral adiposity in men with type 2 diabetes. Int J Androl 2007; 30: 500-7.
32. Gazzaruso C, Giordanetti S, De Amici E, et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004; 110: 22-6.
33. Bansal TC, Guay AT, Jacobson J, et al. Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction. J Sex Med 2005; 2: 96-103.
34. Shabsigh R, Perelman MA, Lockhart DC, et al. Health issues of men: prevalence and correlates of erectile dysfunction. J Urol 2005; 174: 662-7.
35. Kupelian V, Shabsigh R, Araujo AB, et al. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol 2006; 176: 222-6.
36. Shabsigh R, Rajfer J, Aversa A, et al. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract 2006; 60: 1087-92.
37. Shabsigh R, Arver S, Channer KS, et al. The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Pract 2008; 62: 791-8.
38. Jones TH. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab 2010; 21: 496-503.
39. Brooke JC, Walter DJ, Kapoor D, et al. Testosterone deficiency and severity of erectile dysfunction are independently associated with reduced quality of life in men with type 2 diabetes. Andrology 2014; 2: 205-211.
40. Novak A, Brod M, Elbers J. Andropause and quality of life: findings from patient focus groups and clinical experts. Maturitas 2002; 43: 231-7.
41. Zohdy W, Kamal EE, Ibrahim Y. Androgen deficiency and abnormal penile duplex parameters in obese men with erectile dysfunction. J Sex Med 2007; 4: 797-808.
42. Zhang XH, Filippi S, Morelli A, et al. Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. J Sex Med 2006; 3: 253-64; discussion 264-255, author reply 265-256.
43. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
44. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363: 123-35.
45. Kirby M. Identification, management of risk factors. In: Kirby M, ed. Erectile dysfunction and vascular disease. Oxford, UK: Blackwell Publishing; 2003: 35-42.
46. Tamler R, Deveney T. Hypogonadism, erectile dysfunction, and type 2 diabetes mellitus: what the clinician needs to know. Postgrad Med 2010; 122: 165-75.
47. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036-41.
48. Selvin E, Feinleib M, Zhang L, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007; 30: 234-8.
49. Muller M, Grobbee DE, den Tonkelaar I, et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618-23.
50. Tibblin G, Adlerberth A, Lindstedt G, Björntorp P. The pituitary-gonadal axis and health in elderly men: a study of men born in 1913. Diabetes 1996; 45: 1605-9.
51. Dhindsa S, Prabhakar S, Sethi M, et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 5462-8.
52. Ota K, Suehiro T, Ikeda Y, et al. Diabetes mellitus associated with Klinefelter's syndrome: a case report and review in Japan. Intern Med 2002; 41: 842-7.
53. Cho NH, Ahn CW, Park JY, et al. Prevalence of erectile dysfunction in Korean men with Type 2 diabetes mellitus. Diabet Med 2006; 23: 198-203.
54. Palumbo PJ. Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes. Am J Med Sci 2007; 334: 466-80.
55. Aversa A, Bruzziches R, Francomano D, et al. Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine? Ther Adv Urol 2009; 1: 179-97.
56. Thompson J, Khalil RA. Gender differences in the regulation of vascular tone. Clin Exp Pharmacol Physiol 2003; 30: 1-15.
57. Baba K, Yajima M, Carrier S, et al. Delayed testosterone replacement restores nitric oxide synthase-containing nerve fibres and the erectile response in rat penis. BJU Int 2000; 85: 953-8.
58. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899-906.
59. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011; 34: 828-37.
60. Yassin AA, Saad F. Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido). World J Urol 2006; 24: 639-44.
61. Burkhauser RV, Cawley J. Beyond BMI: the value of more accurate measures of fatness and obesity in social science research. J Health Econ 2008; 27: 519-29.
62. Berman DS, Cheng VY, Dey D. Not all body fat weighs equally in the acceleration of coronary artery disease. JACC Cardiovasc Imaging 2010; 3: 918-20.
63. Yu YH, Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res 2005; 96: 1042-52.
64. Traish AM, Toselli P, Jeong SJ, Kim NN. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl 2005; 26: 242-8.
65. Yassin A, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obes 2013; 3: 73-83.
66. Feldman HA, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 2000; 30: 328-38.
67. Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol 2004; 43: 1405-11.
68. Jackson G, Boon N, Eardley I, et al. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int J Clin Pract 2010; 64: 848-57.
69. Jackson G, Betteridge J, Dean J, et al. A systematic approach to erectile dysfunction in the cardiovascular patient: a Consensus Statement-update 2002. Int J Clin Pract 2002; 56: 663-71.
70. Jones TH. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab 2010; 21: 496-503.
71. Giltay EJ, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 2010; 7: 2572-82.
72. Araujo AB, Dixon JM, Suarez EA, et al. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96: 3007-19.
73. Greenstein A, Chen J, Miller H, et al. Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 1997; 9: 123-6.
74. Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. J Endocrinol 2013; 217: R47-71.
75. Yassin DJ, Doros G, Hammerer PG, Yassin A. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med 2014; 11: 1567-76